Weight variability and diabetes complications

Prattichizzo, Francesco; Frigé, Chiara; Grotta, Rosalba La; Ceriello, Antonio

doi:10.1016/j.diabres.2023.110646

Cited by 7 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weight variability is suggested to contribute to adipocyte enlargement and an increase in lipogenic enzymes, myristic acid, palmitic acid, palmitoleic acid, and stearic acid, resulting in glucose metabolism impairment ( 35 , 36 ). Previous studies have found an independent association between high weight variability and incident diabetes ( 37 – 39 ), although only a few prospective studies have examined the correlation of BMI variability with the slope and alterations in cardiovascular risk factors using multiple linear regression ( 19 , 20 , 40 ). These studies suggested that BMI variability was associated with HbA1C levels but not SBP or TC.…”

Section: Discussionmentioning

confidence: 99%

The association of body mass index variability with cardiovascular disease and mortality: a mediation analysis of pooled cohorts

Mehran,

Honarvar,

Masoumi

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

AimWe aimed to investigate the effect of BMI variability on CVD and mortality and to explore the mediation effects of the main cardiovascular risk factors contributing to this association.MethodParticipants aged 40-65 years were pooled from three cohort studies(ARIC [Atherosclerosis Risk in Communities], MESA [Multi-ethnic Study of Atherosclerosis], and TLGS [Tehran Lipid and Glucose Study]. We employed root mean squared error of the fractional mixed model to calculate BMI variability in the measurement period. In the event assessment period, the hazard ratios for CVD and mortality were estimated using Cox proportional hazard regression models. In the next step, the mediation and interaction effects of fasting plasma glucose, total cholesterol, and systolic blood pressure were determined.ResultsA total of 19073 participants were included in this pooled analysis. During a median of 20.7 years of follow-up, 3900 (20.44%) CVD and 6480 (33.97%) all-cause mortality events were recorded. After adjusting for potential confounders, BMI variability was linked to the 1.3 (1.2-1.4) and 1.7 (1.6-1.8) increased risk of CVD and mortality, respectively. Fasting plasma glucose mediated approximately 24% and 8% of the effect of BMI variability on CVD and mortality, respectively. However, systolic blood pressure and total cholesterol did not have mediation effects in this association.ConclusionHigh BMI variability is independently associated with the development of CVD and mortality. This association is partly mediated through fasting plasma glucose. Modern cardiometabolic therapies that lower fasting glucose may reduce the risk of future CVD and mortality in individuals with high BMI variability.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of body mass index variability with cardiovascular disease and mortality: a mediation analysis of pooled cohorts

Mehran,

Honarvar,

Masoumi

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…In addition to obesity being associated both with diabetes and with cardiovascular disease (CVD), body weight variability is associated with development of diabetes, particularly among people with diabetes both with microvascular disease outcomes and, as shown in a recent review, with CVD outcomes. Such studies suggest that we should focus both on measures to reduce weight and to stabilize weight among people with diabetes, with glucagon‐like peptide (GLP)‐1 receptor activators and related medications offering a dual approach to both weight loss and weight stabilization 2 …”

Section: Body Weight Obesity and Gut Hormone‐based Treatment Approachesmentioning

confidence: 99%